Fig. 1: Preparation and characterization of PLX-NP-P-aPD-1@Gel.

a Schematic illustration of the mechanism of tumor immune suppressive microenvironment modulation capability of PLX-NP and P-aPD-1 loaded alginate-based hydrogel in the tumor recurrence model. MHC, major histocompatibility complex; TCR, T-cell receptor. b Release profile of PLX-NP in vitro at pH of 6.5. Data are presented as mean ± s.d. (n = 3). c Confocal microscopy images of anti-PD-1-conjugated platelets. Scale bar, 20 µm. Green: FITC-labeled aPD-1; Red: WGA 594-labeled platelet. The experiments were repeated three times. d Confocal microscopy images of NP and P-aPD-1 in the hydrogel. Scale bar, 50 µm. Green: FITC-labeled NP; Red: Rhodamine B-labeled P-aPD-1. The experiments were repeated three times. e The Cryo SEM image of PLX-NP and P-aPD-1 co-loaded hydrogel. (Scale bar = 2 µm, red arrow: platelets, green arrow: PLX-NP). The experiments were repeated three times. f, g The in vitro release profiles of platelets (f) and aPD-1 (g) from the hydrogel. Data are presented as mean ± s.d. (n = 3). h, i Degradation profile of Cy5.5-alginate hydrogel in vivo represented by radiant efficiency (h) and IVIS spectrum imaging (i). Data are presented as mean ± s.d. (n = 3 mice). Source data are provided as a Source Data file.